A Record Year 2023 for Novel Drug Approvals by the FDA/CDER The estimated cost of developing a single FDA-approved drug is around $2.6 billion. The year 2023 has been a remarkable one for the pharmaceutical industry, as the FDA/CDER has approved 56 novel drugs, a 51% increase compared to 2022. #fda #drugapproval #innovation Here are some of the highlights and trends from the novel drug approvals in 2023: 🏆 Pfizer leads the pack with 6 approvals, followed by Biogen with 4, and AstraZeneca, Chiesi, and UCB with 3 each. #Pfizer #Biogen #AstraZeneca #Chiesi #UCB 🩺 Oncology remains the most popular therapeutic area, with 17 approvals, followed by neurology and autoimmune disorders, with 6 each. #Oncology #Neurology #Autoimmune #DrugApprovals 💊 Small molecules account for more than half of the approvals, with 31, followed by therapeutic monoclonal antibodies, with 12. #SmallMolecules #MonoclonalAntibodies #PharmaTrends 🧬 DNA/RNA based drugs, such as gene therapies and antisense oligonucleotides, are gaining traction, with 4 approvals. #GeneTherapy #RNA #Innovation 🌱 Other novel drugs include a natural extract, a radioactive diagnostic agent, and a fusion protein. #NaturalExtract #DiagnosticAgent #FusionProtein The novel drug approvals in 2023 reflect the diversity and innovation of the pharmaceutical industry, as well as the commitment and collaboration of the FDA/CDER to bring safe and effective treatments to the patients who need them. #pharmainnovation #patientcare #healthcareinnovation If you want to learn more about the novel drug approvals in 2023, you can check out this link: https://lnkd.in/gQ_kU7Tr 📰 #DrugApprovals #pharmanews #medicaladvancements 👉👉You can also check out this insightful analysis by Aaher Mullard in #NatureReviews, which covers the historical data of drug approval, the competition and innovation in the field, and the #DrugDiscovery expectations for 2024. You can find Aasher’s article on the following link: https://lnkd.in/ejHvaxT6
